Translational neuroscience : toward new therapies / edited by Karoly Nikolich and Steven E. Hyman ; Program Advisory Committee, Steven E. Hyman, Julia Lupp, Robert C. Malenka, Karoly Nikolich, Menelas N. Pangalos, and Bernd Sommer
Intro; Contents; The Ernst Strüngmann Forum; List of Contributors; 1 -- Introduction; Neurodevelopmental Disorders: A New Beginning; Neurodegenerative Diseases:Coming Unstuck; New Tools to Drive Future Therapies; From Cellular and Animal Models to Patients; Epilogue; Bibliography; Subject Index; 2 -- What Do We Know about Early Onset Neurodevelopmental Disorders?; 3 -- Psychotic Disorders and the Neurodevelopmental Continuum; 4 -- Neurodevelopmental Disorders; 5 -- Neurodegenerative Diseases; 6 -- Preclinical and Clinical Understanding; 7 -- Neurodegenerative Diseases
8 -- How Might We Get from Genes to Circuits to Disease?9 -- How Do We Define and Modulate Circuits in Animals That Are Relevant to Pathophysiology in Humans?; 10 -- Pathophysiological Toolkit; 11 -- Using a Stem Cell-Based Approach to Model Neurodegenerative Disease; 12 -- From Rodent Behavioral Models to Human Disorders; 13 -- Bridging the Gap between Patients and Models; 14 -- The Revolution Has Begun
Summary
Today, translational neuroscience faces significant challenges. Available therapies to treat brain and nervous system disorders are extremely limited and dated, and further development has effectively ceased. Disinvestment by the private sector occurred just as promising new technologies in genomics, stem cell biology, and neuroscience emerged to offer new possibilities. In this volume, experts from both academia and industry discuss how novel technologies and reworked translation concepts can create a more effective translational neuroscience. The contributors consider such topics as using genomics and neuroscience for better diagnostics and biomarker identification; new approaches to disease based on stem cell technology and more careful use of animal models; and greater attention to human biology and what it will take to make new therapies available for clinical use
